PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

BackgroundProstate specific membrane antigen (PSMA) PET imaging has recently gained attention in glioblastoma (GBM) patients as a potential theranostic target for PSMA radioligand therapy. However, PSMA PET has not yet been established in a murine GBM model. Our goal was to investigate the potential...

Full description

Bibliographic Details
Main Authors:	Maximilian A. Kirchner, Adrien Holzgreve, Matthias Brendel, Michael Orth, Viktoria C. Ruf, Katja Steiger, Dennis Pötter, Lukas Gold, Marcus Unterrainer, Lena M. Mittlmeier, Enio Barci, Roland E. Kälin, Rainer Glass, Simon Lindner, Lena Kaiser, Jessica Maas, Louisa von Baumgarten, Harun Ilhan, Claus Belka, Johannes Notni, Peter Bartenstein, Kirsten Lauber, Nathalie L. Albert
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Oncology
Subjects:	Prostate specific membrane antigen (PSMA) 18F-PSMA-1007 PET glioblastoma GL261 preclinical mouse
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.774017/full

Similar Items

Longitudinal [<sup>18</sup>F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
by: Adrien Holzgreve, et al.
Published: (2022-03-01)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
by: Vinh Ngoc Bui, et al.
Published: (2023-11-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
by: Sadahiro Naka, et al.
Published: (2020-07-01)

PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h
by: Erland Hvittfeldt, et al.
Published: (2023-05-01)

Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
by: Jens Cardinale, et al.
Published: (2017-09-01)

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)

Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
by: Sebastian Hoberück, et al.
Published: (2021-10-01)

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis
by: Cristina E. Popescu, et al.
Published: (2024-04-01)

The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
by: Jun-jie Hong, et al.
Published: (2020-11-01)

18F-FLUORIDE PET/CT vs 18F-PSMA-1007 TO DETECT BONE METASTASES IN PROSTATE CANCER – A HEAD-TO-HEAD PROSPECTIVE COMPARISON
by: Beatriz Birelli do Nascimento, et al.
Published: (2024-04-01)

[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
by: Moritz B. Bastian, et al.
Published: (2024-10-01)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on <sup>18</sup>F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
by: Lena M. Mittlmeier, et al.
Published: (2021-03-01)

Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [<sup>18</sup>F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer
by: Ines Katzschmann, et al.
Published: (2021-02-01)

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
by: Elin Trägårdh, et al.
Published: (2020-05-01)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
by: Simon Sirtl, et al.
Published: (2021-01-01)

Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
by: Lena M. Mittlmeier, et al.
Published: (2021-05-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
by: Ida Sonni, et al.
Published: (2023-10-01)

Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
by: Sandra Resch, et al.
Published: (2023-02-01)

Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake
by: Miguel Mendoza-Ávila, et al.
Published: (2024-03-01)

Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study
by: Philip Alexander Glemser, et al.
Published: (2024-11-01)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2021-10-01)

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2017-11-01)

A Critical Analysis of the Robustness of Radiomics to Variations in Segmentation Methods in <sup>18</sup>F-PSMA-1007 PET Images of Patients Affected by Prostate Cancer
by: Giovanni Pasini, et al.
Published: (2023-12-01)

Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study
by: Junjie Fan, et al.
Published: (2025-02-01)

Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007
by: Stephanie Robu, et al.
Published: (2018-04-01)

An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
by: Jun Dang, et al.
Published: (2023-08-01)

Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer
by: Yuping Zeng, et al.
Published: (2022-06-01)

Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer
by: Zhuonan Wang, et al.
Published: (2022-11-01)

ДИАГНОСТИЧЕСКИЕ ВОЗМОЖНОСТИ ПЭТ/КТ С 18F-PSMA-1007 В ОБНАРУЖЕНИИ МЕТАСТАТИЧЕСКОГО ПОРАЖЕНИЯ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
by: S. L. Polyakov, et al.
Published: (2022-11-01)

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
by: Xing Zhou, et al.
Published: (2021-02-01)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2018-03-01)

Analysis of Pros and Cons in Using [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
by: Costantina Maisto, et al.
Published: (2022-06-01)

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
by: Mikhail Rumiantcev, et al.
Published: (2023-09-01)

The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic Glioblastoma
by: Lukas Gold, et al.
Published: (2024-01-01)

Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer
by: Xiao-Bo Niu, et al.
Published: (2024-12-01)

A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer
by: Zhenyan Ye, et al.
Published: (2024-07-01)

18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
by: Siying Dong, et al.
Published: (2022-12-01)